Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

Award Number: SC1GM140982
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/17/2021
PERIOD OF PERFORMANCE END DATE: 09/21/2025

Group Awards By:

View Award Description

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer - Pancreatic cancer (PanCa) treatment is exceptionally difficult due to the extremely poor response to available therapeutic options. This poor response is mainly due to dysregulation of ribosome biogenesis and desmoplastic pancreatic tumor microenvironment. The main objective of this SC1 proposal is to establish a rationale based novel therapeutic regimen for the treatment of advanced stage pancreatic cancer (PanCa). This novel therapy will provide therapeutic benefit and circumvent chemoresistance via simultaneous targeting of ribosome biogenesis by RNA polymerase I inhibitor (BMH-21) and desmoplastic tumor microenvironment with hyaluronan inhibitor (4-Methylumbelliferone). The ribosome biogenesis is the complex and highly coordinated cellular process leading to the production of ribosomes. This process is aberrantly operated during the development of cancer, including PanCa and also involved in chemoresistance to therapeutic drugs, such as including gemcitabine. Hyaluronan (Hyaluronic acid) is one of the major components of the extracellular matrix secreted by fibroblasts and pancreatic stellate cells which is involved in the formation of desmoplasia in pancreatic tumors that prevent drug accessibility in the tumors. Thus, strategically targeting of both ribosome biogenesis and hyaluronan synthesis will effectively suppress the growth and metastasis of pancreatic tumors. BMH-21 was recently developed as a potent selective inhibitor of RNA polymerase that has shown potent anti-cancer effect in pre-clinical studies. Our preliminary results have shown promising anti-cancer and chemosensitization effects of BMH-21 in PanCa models. 4-Methylumbelliferone (4-MU) is a non-toxic hyaluronic acid synthesis inhibitor with an anti-cancer property that has never been tested in combination with BMH-21 for PanCa treatment. BMH- 21 demonstrated remarkable tumor growth inhibition in the orthotopic tumor xenograft mouse model when combined with 4-MU. Based on these compelling evidences, we hypothesize that the combination of BMH-21 and 4-MU proffers a pronounced anti-cancer efficacy due to improved drug uptake into tumors via repression of desmoplasia and ribosome biogenesis processes. Three specific aims are proposed. In Aim 1, we plan to investigate underlying molecular mechanisms and functional impact of BMH-21 and 4-MU to inhibit the growth, metastatic phenotypes, and overcome chemoresistance. In Aim 2, we will investigate whether and how BMH-21 and 4-MU combination inhibits pancreatic tumor growth and metastasis in an orthotopic xenograft mouse model. Under Aim 3, we will elucidate the therapeutic and chemosensitization efficacy of BMH-21 and 4-MU combination in a transgenic mouse model (KPC) of PanCa. We will also determine how this combination influences pancreatic tumor immune surveillance. This study has a high significant translational impact on the clinic as it will establish a new rationale-based therapy for the treatment of advanced metastatic PanCa in humans. Successful completion of this SC1 proposal will set a strong foundation for the PI and his research team to further pursue an NIH competitive grant (i.e. R01 or R21) for future clinically related studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	THE UNIVERSITY OF TEXAS RIO GRANDE VALLEY	1201 W UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	000	4	1/15/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $363,250 )
2024	2024	THE UNIVERSITY OF TEXAS RIO GRANDE VALLEY	1201 W UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	000	4	3/22/2024	NON-COMPETING CONTINUATION	$326,925
2024	2024	THE UNIVERSITY OF TEXAS RIO GRANDE VALLEY	1201 W UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	001	4	6/18/2024	NON-COMPETING CONTINUATION	$36,325
														Subtotal = $363,250

Issue Date FY: 2023 ( Subtotal = $363,250 )
2023	2023	UNIVERSITY OF TEXAS RIO GRANDE VALLEY	1201 W UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	000	3	3/31/2023	NON-COMPETING CONTINUATION	$363,250
														Subtotal = $363,250

Issue Date FY: 2022 ( Subtotal = $363,250 )
2022	2022	UNIVERSITY OF TEXAS RIO GRANDE VALLEY, THE	1201 WEST UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	000	2	4/8/2022	NON-COMPETING CONTINUATION	$326,925
2022	2022	UNIVERSITY OF TEXAS RIO GRANDE VALLEY, THE	1201 WEST UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	001	2	6/15/2022	NON-COMPETING CONTINUATION	$36,325
														Subtotal = $363,250

Issue Date FY: 2021 ( Subtotal = $363,250 )
2021	2021	UNIVERSITY OF TEXAS RIO GRANDE VALLEY, THE	1201 WEST UNIVERSITY DR	EDINBURG	TX	78539	HIDALGO	USA	Biomedical Research and Research Training	000	1	5/17/2021	NEW	$363,250
														Subtotal = $363,250

Grand Total All Awards = $1,453,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

Award Number: SC1GM140982

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/17/2021

PERIOD OF PERFORMANCE END DATE: 09/21/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer